Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome

Annals of Hematology

Volumn 94, Issue 8, 2015, Pages 1291-1299

  Isert, Mecki ^a   Miesbach, Wolfgang ^a   Schüttfort, Gundolf ^a   Weil, Yvonne ^a   Tirneci, Vanessa ^a   Kasper, Alexander ^a   Weber, Adele ^a   Lindhoff Last, Edelgard ^a   Herrmann, Eva ^a   Linnemann, Birgit ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anticoagulant therapy; Antiphospholipid syndrome; Chromogenic factorX assay; International normalized ratio; Lupus anticoagulants

Indexed keywords

LUPUS ANTICOAGULANT; PHENPROCOUMON; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLOOD COLLECTION TUBE; CHROMOGENIC FACTOR XIII ASSAY; CLINICAL ARTICLE; COAGULOMETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MECHANICAL HEART VALVE; PATIENT MONITORING; POINT OF CARE SYSTEM; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOELASTOGRAPH; VENOUS THROMBOEMBOLISM; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; COHORT ANALYSIS; DRUG EFFECTS; DRUG MONITORING; FOLLOW UP; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RABBIT;

ADULT; AGED; ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; COHORT STUDIES; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; RABBITS; VITAMIN K;

EID: 84941082205     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-015-2374-3     Document Type: Article

References (34)

1. Du VX, Kelchtermans H, de Groot PG, de Laat B (2013) From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 132:319-326
2. Favaloro EJ, Wong RC (2011) Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 49:447-461
3. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N et al (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8:237-242
4. Favaloro EJ, McVicker W, Hamdam S, Hocker N (2010) Improving the harmonisation of the international normalized ratio (INR): time to think outside the box? Clin Chem Lab Med 48: 1079-1090
5. WHO Expert Committee on Biological Standardization (1999) Guidelines for thromboplastins and plasma used to monitor oral anticoagulant therapy. World Health Organization Technical Report Series; no. 889. Geneva, WHO
6. Crowther M, Crowther MA (2010) Intensity of warfarin coagulation in the antiphospholipid syndrome. Curr Rheumatol Rep 12:64-69
7. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, Committee B, British Committee for Standards in Haematology (2012) Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47-58
8. Poller L (2004) International normalized ratios (INR): the first 20 years. J Thromb Haemost 2:849-860
9. Smith SA, Comp PC, Mirrissey JH (2006) Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost 4:820-827
10. Robert A, Le Querrec A, Delahousse B, Caron C, Houbouyan L, Boutière B et al (1998) Control of oral anticoagulation in patients with the antiphospholipid syndrome-influence of the lupus anticoagulant on international normalized ratio. Thromb Haemost 80: 99-103
11. Rosborough TK, Shepherd MF (2004) Unreliability of international normalized ratio for monitoring warfarin therapy in patients with lupus anticoagulant. Pharmacotherapy 24:838-842
12. Lawrie AS, Purdy G, Mackie IJ, Machin SJ (1997) Monitoring oral anticoagulation therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 98:887-892
13. Bijsterveld NR, Middeldorp S, Berends F, Büller HR (2000) Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulants: effect on different tests for INR determination. J Thromb Thrombolysis 9:263-269
14. Tripodi A, Chantarangkul V, Clerici M, Negri B, Galli M, Mannucci PM (2001) Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 115: 672-678
15. Crowl A, Schullo-Feulner A, Moon JY (2014)Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant. Ann Pharmacother 48:1479-1483
16. Plesch W, Wolf T, Breitenbeck N, Dikkeschei LD, Cervero A, Perez PL et al (2008) Results of the performance verification of the CoaguChek XS system. Thromb Res 123:381-389
17. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7:1737-1740
18. Brandt JT, Triplett DA, Alving B, Scharrer I (1995) Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 74:1185-1190
19. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295-306
20. McGlasson DL, Romick BG, Rubal BJ (2008) Comparison of a chromogenic factor X assay with international normalized ratio for monitoring oral anticoagulation therapy. Blood Coagul Fibrinolysis 19:513-517
21. Baumann Kreuziger LM, Datta YH, Johnson AD, Zantek ND, Shanley R, Reding MT (2014) Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing. Blood Coagul Fibrinolysis 25:232-236
22. Della Valle P, Crippa L, Garlando AM, Pattarini E, Safa O, D’Angelo V et al (1999) Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in antiphospholipid-antibody syndrome. Haematologica 84: 1065-1074
23. Rosborough TK, Jacobsen JM, Shepherd MF (2009) Relationship between chromogenic factor X and international normalized ratio differs during early warfarin initiation compared with chronic warfarin administration. Blood Coagul Fibrinolysis 20:433-435
24. Remijn JA, Lucas S, Wildeboer B, van Suijlen JD, Adriaansen HJ (2008) Strongly increased international normalized ratio with recombinant Neoplastin R compared with tissue extract Neoplastin Plus in patients initiating oral anticoagulation therapy: implications for anticoagulation dosage. Clin Chem 54:1929-1931
25. Remijn JA, Wildeboer B, van Suijlen JDE, Adiaansen HJ (2011) Recombinant thromboplastins vs. tissue-extract thromboplastins in patients on unstable oral anticoagulant therapy. Clin Chem 57:916-917
26. Solvik UO, Roraas TH, Petersen PH, Stavelin AV, Monsen G, Sandberg S (2012) Effect of coagulation factors on discrepancies in international normalized ratio results between instruments. Clin Chem Lab Med 50:1611-1620
27. Carrasco C, Campbell B, Shiach C (2004) Effects of the lupus anticoagulant on the control of oral anticoagulant treatment. Br J Haematol 124:555-563
28. Shermock KM, Streiff MB, Pinto BL, Kraus P, Pronovost PJ (2011) Novel analysis of clinically relevant diagnostic errors in point-ofcare devices. J Thromb Haemost 9:1769-1775
29. Barcellona D, Fenu L, Vannini ML, Piras M, Marongiu F (2012) Antiphospholipid syndrome patients: the performance of CoaguChek XS in monitoring of vitamin K antagonists. Thromb Res 129:e168-e170
30. Christensen TD, Larsen TB, Jensen C, Maegaard M, Sorensen B (2009) International normalized ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy. Thromb Haemost 101:563-569
31. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P (2006) Self-monitoring of oral anticoagulation: a systemic review and meta-analysis. Lancet 367: 404-411
32. Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM (2007) Self-management of oral anticoagulant therapy: a systemic review and meta-analysis. Int J Cardiol 118:54-61
33. Schulman S, Kearon C, on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost 3:692-694
34. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-S266